Candel Therapeutics (CADL) Total Non-Current Liabilities (2020 - 2025)

Candel Therapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $57.7 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 42.27% year-over-year to $57.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $57.7 million (up 42.27% YoY) and the FY2025 annual result came in at $57.7 million, up 42.27% from the prior year.
• Total Non-Current Liabilities advanced to $57.7 million in Q4 2025 per CADL's latest filing, from $40.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $57.7 million in Q4 2025 and troughed at $5.5 million in Q3 2021.
• A 5-year average of $25.2 million and a median of $26.8 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 411.57% in 2022, then dropped 21.49% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $6.8 million in 2021, then surged by 312.19% to $28.1 million in 2022, then dropped by 1.98% to $27.5 million in 2023, then surged by 47.2% to $40.5 million in 2024, then soared by 42.27% to $57.7 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $57.7 million, $40.5 million, and $20.9 million for Q4 2025, Q4 2024, and Q3 2024 respectively.